Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan

PURPOSE: Our preliminary report of imatinib mesylate (IM) in gastrointestinal stromal tumor (GIST) patients detailed a high response rate; however, the long-term result is still unknown. We conducted an analysis of Taiwan advanced inoperable/metastatic GIST patients treated on IM regarding survival,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yeh, Chun-Nan, Chen, Yen-Yang, Tseng, Jeng-Hwei, Chen, Jen-Shi, Chen, Tsung-Wen, Tsai, Chun-Yi, Cheng, Chi-Tung, Jan, Yi-Yin, Chen, Miin-Fu
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press Inc. 2011
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243655/
https://ncbi.nlm.nih.gov/pubmed/22190996
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky